Vineet Laboratories Limited
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
What Vineet files
- Others52
- Important44
- Board Meeting14
- Updates8
- QIP/Rights/Pref.2
- Insider Trade2
Vineet Laboratories' board has approved its financial results for the quarter and year ended March 31. The company turned profitable (0.13 Cr PBT) from a significant loss. Share issuance brought 29.08 Cr, boosting equity and cash to 16.70 Cr. Long-term borrowings decreased to 35.29 Cr.
Vineet Labs' board met, approving its audited standalone financial results for Q4 & FY ended March 31, 2026. FY26 net sales hit ₹58.40 Cr with a profit of ₹1.11 Cr & EPS of ₹1.00. Long-term borrowings decreased to ₹35.29 Cr from ₹39.09 Cr.
Vineet Labs' board approved audited standalone financial results for the fourth quarter and full year ended March 31, 2026. FY26 net sales stood at ₹58.40 Cr, with a profit of ₹1.11 Cr.
Please find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 2026
Vineet Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__